Clinical trials: Opiate Dependency Relapse
Opioid Addiction
Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
This study proposes to use functional magnetic resonance imaging (FMRI) to observe brain activity and behavior associated with decision-making about rewards (DD task), working memory and working memory cognitive persistence (WM…
- Trial name
- NCT02696096
- Testing
- FMRI, Suboxone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Butler Hospital
Opioid-Related Disorders
Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1
Lofexidine is an experimental medication that may be beneficial in reducing opiate withdrawal symptoms, such as sleep difficulty, anxiety, and tension.
- Trial name
- NCT00142909
- Testing
- Lofexidine
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Yale University
Prescription Opiate/Medication Dependence
CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery
The proposed project will use fMRI and specific probes of reward and inhibition as biomarkers predicting drug use during and after treatment in 72 subjects addicted to prescription opioids/medications.
- Trial name
- fMRI CURE (NCT01587196)
- Testing
- Vivitrol
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Pennsylvania
Opioid Dependence, HIV
Relapse Prevention to Reduce HIV Among Women Prisoners
This study is a feasibility and acceptability study assessing whether providing buprenorphine for women under criminal justice supervision leaving a controlled environment and returning to the community would prevent opioid…
- Trial name
- NCT00763958
- Testing
- Buprenorphine
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Opiate Dependence
Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
This pilot study's primary aim is to compare rates of sustained opioid relapse, defined as self-reported opioid use >50% (>15 of 30) of days during the first 30 days following release from jail, among persons treated with XR-NTX…
- Trial name
- NCT01180647
- Testing
- Extended-Release Naltrexone, Motivational Enhancement Counseling
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- NYU Langone Health